Table 4.
Association of Antidepressant Medication Type With Incident CVD Considering Antidepressant Type by Period of Reported Use (Before 1994, After 1994) in the ARIC Cohort Study
| Outcomes | ||||
|---|---|---|---|---|
| AF | HF | MI | Ischemic Stroke | |
| No. of events, total | 332 | 365 | 174 | 119 |
| Median follow‐up, overall (y) | 13.4 | 13.6 | 13.5 | 14.5 |
| Before 1994, y | 21.4 | 21.6 | 22.4 | 22.2 |
| After 1994, y | 5.4 | 5.4 | 5.3 | 5.2 |
| HR (95% CI)a | ||||
|---|---|---|---|---|
| SSRI vs non‐SSRI, on or prior to 1994 | 0.99 (0.67–1.45) | 1.14 (0.79–1.63) | 0.66 (0.37–1.16) | 0.75 (0.39–1.45) |
| SSRI vs non‐SSRI, after 1994 | 1.20 (0.87–1.67) | 0.89 (0.65–1.21) | 1.16 (0.72–1.86) | 1.52 (0.81–2.86) |
| P value for interactionb | 0.44 | 0.31 | 0.13 | 0.13 |
Model=adjustment for vital exhaustion questionnaire, BMI, cigarette smoking, alcohol use, antihypertensive medications, diabetes mellitus, and the year of diagnosis. AF indicates atrial fibrillation; ARIC, Atherosclerosis Risk in Communities; BMI, body mass index; CVD, cardiovascular disease; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; SSRI, selective serotonin reuptake inhibitor.
a
HR for each outcome comparing the exposure of using SSRI medications as compared with non‐SSRI medications.
b
SSRI‐by‐year interaction P value.